A retrospective study assessing the impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming resistance strategies for resistance

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

19 Jan 2022 Results describing a case series of six patients who, after acquiring resistance to their initial osimertinib treatment were rechallenged with osimertinib following intervening carboplatin-based chemotherapy published in the Clinical Drug Investigation
06 Jul 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com